A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot



Status:Active, not recruiting
Conditions:Cardiology, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:5/12/2018
Start Date:June 13, 2016
End Date:December 31, 2019

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Risk of Major Bleeding Associated With Apixaban Verses Warfarin in the Treatment of Venous Thromboembolism in US Clinical Practice

A study to compare the risk of a major bleeding in participants who received 2 different
blood thinning medications following a blood clot


Inclusion Criteria:

- An acute-care inpatient encounter with a principal or secondarydiagnosis of VTE, or an
ambulatory-care encounter with any diagnosis of VTE

- An outpatient pharmacy claim for apixaban or warfarin during the 30-day period
following the index encounter

- Continuous and comprehensive medical/drug coverage for ≥6 months preceding the index
encounter

Exclusion Criteria:

- Evidence of a trial fibrillation/flutter or chemotherapy/radiation therapy for
malignancy (other than non-melanoma skin cancer) during 6-month period preceding first
receipt of index therapy

- Evidence of VTE(VTE event)during 6-month period preceding index encounter

- Evidence of malignancy (other than non-melanoma skin cancer) during 90-day period
preceding first receipt of index therapy

Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
1
site
Local Institution
Princeton, New Jersey 08540
?
mi
from
Princeton, NJ
Click here to add this to my saved trials